It is used as an adjunct to diet and exercise in adults with type 2 diabetes mellitus. It can be used as monotherapy or in combination with other oral agents. It lowers A1C by o.5% (1-4). Adverse reactions were uncommon, but include nasopharyngitis, hyperlipidemia, cough, hypertriglyceridemia, and weight gain (5).
As it is eliminated via the enterohepatic system, no dose adjustment is necessary in patients with renal or hepatic impairment.
References
1. Diabetes Obes Metab 2011;13:65.
2. Diabetes Obes Metab 2011;13:258.
3. Scott LJ. Linagliptin: in type 2 diabetes mellitus. Drugs 2011;71:611.
4. Diabetes Obes Metab 2011.
5. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Tradjenta/Tradjenta.pdf
As it is eliminated via the enterohepatic system, no dose adjustment is necessary in patients with renal or hepatic impairment.
References
1. Diabetes Obes Metab 2011;13:65.
2. Diabetes Obes Metab 2011;13:258.
3. Scott LJ. Linagliptin: in type 2 diabetes mellitus. Drugs 2011;71:611.
4. Diabetes Obes Metab 2011.
5. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Tradjenta/Tradjenta.pdf
No comments:
Post a Comment